Michael Heinrich
Professor of Medicine, School of Medicine · Oregon Health & Science University
Credentials: · · · · ·
History
Research
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
New England Journal of Medicine · 2002 · 3,431 citations
The Lancet · 2006 · 2,046 citations
PDGFRA activating mutations in gastrointestinal stromal tumors
Science · 2003 · First of 13 authors · Corresponding · 1,890 citations
- CC
106 papers
45 papers
38 papers
37 papers
36 papers
34 papers
26 papers
- CB
19 papers
Grants
- 2021–2029
Functional Profiling of Germline SDH Variants Associated with Cancer Susceptibility
Department of Veterans Affairs · I01
Contact PI · Portland Va Medical Center
- 2021–2024
Novel Models for Functional Profiling of Germline SDH Variants Associated with Cancer
National Cancer Institute · R21
Contact PI · $320.4K · Oregon Health & Science University
- 2009–2020
Regulation of Oncogenic KIT by LMTK3
Department of Veterans Affairs · I01
Contact PI · Portland Va Medical Center
Clinical trials
- 2011–2014
Principal investigator · Completed · Phase 2
Arog Pharmaceuticals, Inc.
- 2001–2007
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Principal investigator · Completed · Phase 2
Novartis Pharmaceuticals
- 2025–2030
Site PI · Recruiting · Phase 3
GlaxoSmithKline
- 2018–2029
Site PI · Recruiting · Phase 1
Inhibrx Biosciences, Inc